MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBXNYSE / NASDAQHealthcareSmall cap

$49.55-$3.86 (-7.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
P/E
-16.9x
EV / EBITDA
-14.3x
Revenue
$0.00
ROCE
-26.5%

+83.3% over the last year

MBX Biosciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-7.4%
3M
-25.3%
6M
+57.7%
1Y
+83.3%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$3.86 (-7.2%) from $53 to $50 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MBX, bought on each weekday since 2024.

News & filings

What MBX Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 87.0 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Read moreShow less

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Sector
Healthcare
Shares outstanding
44.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/E
-16.9x
P/B
4.0x
EV / EBITDA
-14.3x
52-week high
$70.70
52-week low
$26.92

Profitability

ROE
-23.6%
ROCE
-26.5%
ROIC
-26.3%
ROA
-22.6%

Growth

Revenue
$0.00
Net profit growth, 1Y
40.5%
Free cash flow
-$81.9M

Solvency

Current ratio
24.62
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.92
Cash / Market cap
5.1%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

MBX Biosciences, Inc. revenue and net profit by fiscal year
MBX Biosciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$26.1M
FY2023$0.00-$32.6M
FY2024$0.00-$61.9M
FY2025$0.00-$87.0M

Cash flows

FY2025: -$79.9M from operations, -$81.9M free after investment (dashed).

MBX Biosciences, Inc. operating and free cash flow by fiscal year
MBX Biosciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$23.1M-$23.6M
FY2023-$32.0M-$32.1M
FY2024-$54.7M-$55.6M
FY2025-$79.9M-$81.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$97.8M
Net profit
-$87.0M
Cash from operations
-$79.9M
Free cash flow
-$81.9M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$97.8M-$87.0M-$81.9M-23.6%—+40.5%

Monthly returns

Month-by-month returns of MBX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$385.1M
Liabilities$15.9M
Equity$369.2M
Paid-in capital$593.4M
Retained earnings-$224.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MBX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): MBX Biosciences, Inc., Maze Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
MBX Biosciences, Inc.MBXthis company$1.5B-16.9x4.0x-23.6%-14.3x
AnaptysBio, Inc.ANAB$1.5B—40.4x-35.6%17.4x
STAAR Surgical CompanySTAA$1.5B-18.5x4.3x-23.4%-36.9x
Perrigo Company plcPRGO$1.5B-1.0x0.5x-48.6%-5.7x
NeoGenomics, Inc.NEO$1.5B-13.6x1.8x-12.9%-44.5x
Monte Rosa Therapeutics, Inc.GLUE$1.5B-38.0x6.3x-16.6%-30.0x
Aveanna Healthcare Holdings Inc.AVAH$1.4B6.4x7.4x115.3%10.3x
Septerna, Inc.SEPN$1.4B-28.9x3.7x-12.8%-16.6x
Maze Therapeutics, Inc.MAZE$1.4B-10.7x4.0x-36.9%-8.8x
Peer median—-13.6x4.1x-20.0%-12.7x

Year-to-date ROI

MBX since 1 January, against earlier years.

Historical volatility

MBX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$98.1M
Research and developmentResearch And Development$79.2M
Total expensesTotal Expenses$98.1M
Pretax incomePretax Income-$87.0M

Learn while you research

Academy chapters picked for MBX Biosciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →